Skip to main content

Table 2 Relationship between circPTEN1 and clinical characteristics in CRC patients (n = 150)

From: circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-β/Smad signaling

   Cases Low expression High expression P
Gender Male 89 46 (61%) 43 (57%) 0.5652
Female 61 29 (39%) 32 (43%)  
Age ≤60 41 19 (25%) 22 (29%) 0.5241
> 60 109 56 (75%) 53 (71%)  
Tumor size (cm) ≤5 28 11 (15%) 17 (23%) 0.1493
> 5 122 64 (85%) 58 (77%)  
Differentiation Well/Moderate 89 42 (56%) 47 (63%) 0.3133
Poor 61 33 (44%) 28 (37%)  
T stage T1 + T2 64 28 (37%) 36 (48%) 0.1156
T3 + T4 86 47 (63%) 39 (52%)  
N stage N0 44 15 (20%) 29 (39%) 0.0032**
N1 + N2 106 60 (80%) 46 (61%)  
M stage M0 130 61 (81%) 69 (92%) 0.0228*
M1 20 14 (19%) 6 (8%)  
Pathological stage I + II 38 12 (16%) 26 (35%) 0.0021**
III + IV 112 63 (84%) 49 (65%)  
  1. *p < 0.05, **p < 0.01. Using median circPTEN1 values as cutoff